Rosiglitazone Maleate is the maleate salt of rosiglitazone, an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. Rosiglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation. It is grouped under the following drug class(es): Hypoglycemics and Thiazolidinediones. Its therapeutic use is listed as antidiabetic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Avandia, Venvia and Nyracta. Its PubChem CID is 5281055.
Rosiglitazone maleate
| CAS No | 155141-29-0 |
|---|---|
| Molecular Formula | C22H23N3O7S |
| Molecular Weight | 473.5 g/mol |
| Synonyms | (Z)-but-2-enedioic acid;5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Rosiglitazone Maleate is the maleate salt of rosiglitazone, an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity.
The listed CAS number is 155141-29-0.
The listed molecular formula is C22H23N3O7S.
The listed molecular weight is 473.5 g/mol.
(Z)-but-2-enedioic acid;5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione.
The source lists Avandia, Venvia and Nyracta.